IL28B genotyping and treatment of HCV infected subjects

1. Averhoff FM, Glass N, Holtzman D. Global Burden of Hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012; 55(Suppl 1): 10-5.10.1093/cid/cis361Open DOISearch in Google Scholar

2. Perz JF, Armstrong GL, Farrington LA, Hutin Y, Bell B. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45:529-38.10.1016/j.jhep.2006.05.013Open DOISearch in Google Scholar

3. De Francesco R. Molecular virology of the hepatitis C virus. J Hepatol. 1999; 31(Suppl 1):47-53.10.1016/S0168-8278(99)80374-2Open DOISearch in Google Scholar

4. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot Ch, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994; 19:1321-4.10.1002/hep.1840190538Open DOISearch in Google Scholar

5. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42:962-73.10.1002/hep.20819Open DOISearch in Google Scholar

6. Caruntu FA, Benea L. Acute hepatitis C virus infection: diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis. 2006; 15:249-56.Search in Google Scholar

7. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology. 2001; 33:321-7.10.1053/jhep.2001.22112Open DOISearch in Google Scholar

8. Koszinowski UH, Reddehase MJ, Jonjic S. The role of CD4 and CD8 T cells in viral infections. Curr Opin Immunol. 1991; 3:471-5.10.1016/0952-7915(91)90005-LSearch in Google Scholar

9. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology. 1999; 30:595-601.10.1002/hep.51030031210462362Open DOISearch in Google Scholar

10. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Inter Med. 2000; 132:296-305.10.7326/0003-4819-132-4-200002150-0000810681285Search in Google Scholar

11. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology. 2003; 38: 4-13.10.1053/jhep.2003.5031012829979Open DOISearch in Google Scholar

12. Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis. 2005; 25:7-17.10.1055/s-2005-86477815731994Open DOISearch in Google Scholar

13. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen ML, Shah NK, et al. IFN-ls mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003; 4:69-77.10.1038/ni87512483210Open DOISearch in Google Scholar

14. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko, SV, MacDonald MR, et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006; 131:1887-98.10.1053/j.gastro.2006.09.05217087946Search in Google Scholar

15. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798-801.10.1038/nature08463317200619759533Search in Google Scholar

16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461:399-401.10.1038/nature0830919684573Search in Google Scholar

17. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, Liu F, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Vir Hepat. 2012; 19:173-81.10.1111/j.1365-2893.2011.01497.x22329371Open DOISearch in Google Scholar

18. Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012; 9: 406-417.10.1038/nrgastro.2012.10122641049Open DOISearch in Google Scholar

19. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138:1338-45.10.1053/j.gastro.2009.12.05620060832Search in Google Scholar

20. Thompson JA. Genetic factors and hepatitis C virus infection. Gastroenterology. 2012; 142:1335-9.10.1053/j.gastro.2012.01.04622537440Search in Google Scholar

21. Tanaka Y, Nishida Y, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41:1105-9.10.1038/ng.44919749757Open DOISearch in Google Scholar

22. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41:1100-4.10.1038/ng.44719749758Open DOISearch in Google Scholar

23. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012; 26:401-12.10.1016/j.bpg.2012.09.00923199500Open DOISearch in Google Scholar

24. Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH. Interleukin-28B polymorphisms on the SVR in the treatment of naive chronic hepatitis C with pegylated interferon-α plus ribavirin: A meta-analysis. Gene. 2012; 507:27-35.10.1016/j.gene.2012.07.02622842190Search in Google Scholar

25. Holmes JA, Desmond PV, Thompson AJ. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat. 2012; 19:677-84.10.1111/jvh.1200322967098Open DOISearch in Google Scholar

26. Thompson AJ, McHutchinson JG. Will IL28B polymorphism remain relevant in the era of directacting antiviral agents for hepatitis C virus? Hepatology. 2012; 56:373-81.10.1002/hep.2579222511355Open DOISearch in Google Scholar

27. King LY, Chung RT. IL28B testing in a rapidly changing world: Still relevant? J Hepatol. 2013; 58:847-9.10.1016/j.jhep.2013.02.00223416431Open DOISearch in Google Scholar

28. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1195-206.10.1056/NEJMoa1010494376684921449783Search in Google Scholar

29. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1207-17.10.1056/NEJMoa1009482315312521449784Search in Google Scholar

30. Jacobson IM, McHutchinson JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364:2405-16.10.1056/NEJMoa101291221696307Search in Google Scholar

31. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364:2417-28.10.1056/NEJMoa101308621696308Search in Google Scholar

32. Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz E, Roberts S, et al. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol. 2013; 58:883-9.10.1016/j.jhep.2012.12.02323321318Open DOISearch in Google Scholar

33. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013; 368:45-53.10.1056/NEJMoa120880923281975Search in Google Scholar

34. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368:34-44.10.1056/NEJMoa120895323281974Search in Google Scholar

35. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatmentexperienced chronic hepatitis C genotype 1 patients. J Med Econ 2014; 17, 65-76.10.3111/13696998.2013.86003324160335Open DOISearch in Google Scholar

36. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014; 17:77-87.10.3111/13696998.2013.84415924032626Open DOISearch in Google Scholar

37. Stedman C. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol. 2013; 28:38-45.10.1111/jgh.1202823137126Open DOISearch in Google Scholar

38. You DM, Pockros PJ. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013; 14:2581-9.10.1517/14656566.2013.85007424138198Search in Google Scholar

39. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012; 56:1247-53.10.1016/j.jhep.2011.12.03322326470Search in Google Scholar

40. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with different expression of intrahepatic interferon stimulated genes in patients with chronic hepatitis C. Hepatology. 2010; 52:1888-96.10.1002/hep.23912365330320931559Open DOISearch in Google Scholar

41. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45:164-71.10.1038/ng.2521379339023291588Open DOISearch in Google Scholar

42. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med. 2013; 10:1109-16.10.1084/jem.20130012367470423712427Open DOISearch in Google Scholar

43. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-G allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis. 2014; 209:350-4.10.1093/infdis/jit433388316223956438Search in Google Scholar

44. Stattermayer AF, Strassl R, Maieron A, Rutter K, Strauber R, Strasser M, et al. Polymorphisms of interferon-l4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014; 39:104-11. 10.1111/apt.1254724205831Search in Google Scholar